You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A method for accurate and sensitive detection of HIV drug-resistant minority variants

    SBC: Medosome Biotec, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Drug resistance to HIV is a major threat to achieving long term viral suppression in HIV individuals Up to of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes and incomplete viral suppression and virologic failure are often associated with drug resistance Therefore current DHHS guideline recomme ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists

    SBC: Bohemica Pharmaceuticals, LLC            Topic: 100

    DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Monitored Breathing Awareness Therapy for Insomnia Disorder in Older Adults

    SBC: ADVANCED MEDICAL ELECTRONICS CORP            Topic: NIA

    DESCRIPTION provided by applicant Insomnia of sufficient clinical severity to meet diagnostic criteria is present in approximately of older adults nearly million individuals n the US alone If left untreated it can lead to increased rates of depression cognitive impairment and cardiovascular disease Treatment relies on pharmacotherapy such as sedative hypnotic therapy which is ass ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Medical Sensor Applications of Tunnel Magnetoresistance TMR

    SBC: Koronis Biomedical Technologies Corp.            Topic: NIDCD

    DESCRIPTION provided by applicant Koronis Biomedical Technologies KBT proposes to develop a novel omnidirectional low power miniaturized hearing aid telecoil replacement module TCRM based on tunneling magnetoresistance TMR technology It has been reported that million Americans have hearing loss Hearing loss affects in Americans and in households Modern telecoils assist ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Novel therapies for inherited muscle diseases

    SBC: Medosome Biotec, LLC            Topic: NIAMS

    DESCRIPTION provided by applicant The pursuit of novel therapies informed by the astounding advances in biomedical science of the past half century has been fruitful for many disorders However inherited muscle diseases such as muscular dystrophy remain stubbornly resistant to sophisticated molecular approaches to therapy A few therapies are finally edging towards approval but it has become ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. A Novel STAT3 Inhibitor Targeting its DNA-Binding Site for Drug Development

    SBC: QRKANSWER LLC            Topic: NCI

    DESCRIPTION provided by applicant Cancer is a major public health problem and a leading cause of mortality claiming more than half million lives every year in the US While major progresses have been made in developing targeted anticancer therapeutics many cancers such as lung cancers have no effective treatments Unfortunately many ideal oncogenic targets including transcription factors for ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. High speed Intraoperative Assessment of Breast Tumor Margin using MarginPAT

    SBC: Vibronix, Inc.            Topic: O

    After a breast conserving therapy histology is often performed to check whether the excised tumor specimen is surrounded by a sufficient amount of normal tissue If a positive margin is identified then a second operation will be performed Currently the re operation rate is which raises a need for intraoperative detection of residual cancers The current intraoperative tools for margin ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. A Novel Biologic for the Treatment of Hypogonadism

    SBC: JangoBio, LLC            Topic: N

    DESCRIPTION provided by applicant Male hypogonadism results from failure of the testes to produce sufficient sex hormones Aging is the greatest cause of primary hypogonadism otherwise known as testosterone deficiency syndrome TDS and in the United States affects million men while undiagnosed cases of TDS are upwards of million men TDS adversely affects male health and has been lin ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Development of peptide inhibitors for neuroinflammation and neurodegeneration

    SBC: PROVAIDYA            Topic: NIA

    DESCRIPTION provided by applicant The prevalence of Alzheimerandapos s disease AD is poised to increase exponentially with the growing aging population worldwide In the United States total annual costs of AD care are projected to increase from $ billion in to over $ trillion in Paucity of disease modifying therapies capable of slowing the disease progression is an acute unmet ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government